Registered title, quoted from ClinicalTrials.gov
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07920822, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically diagnosed as advanced malignant solid tumor;
Inclusion criterion 5
According to RECIST 1.1 standard, at least one measurable tumor lesion. For lesions that have received previous radiotherapy, the lesion can be included in the measurable lesion only when there is clear disease progression after radiotherapy;
Inclusion criterion 8
Toxicity of previous anti-tumor treatment (such as previous chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has recovered to ≤ grade 1 level (except for hair loss);
Inclusion criterion 9
Pregnant women of childbearing age need negative pregnancy test results. Subjects with reproductive capacity (and their partners) voluntarily use effective contraceptive methods during the treatment period and within 6 months after the last use of the investigational drug, such as condoms, oral or injectable contraceptives, etc.
Inclusion criterion 15
Within the 3 months prior to the administration of 177Lu-HX02, the subject had received radiotherapy drugs, including but not limited to: lutetium-177, radium-223, etc.
Exclusion criterion 1
Within the 4 weeks prior to the administration of 177Lu-HX02, the subject had undergone major surgery, chemotherapy, biological therapy, immunotherapy, endocrine therapy (except hormone replacement), large molecule targeted therapy or off-label drug treatment. Within the 2 weeks prior to administration, the subject had received local palliative radiotherapy, traditional Chinese medicine with anti-tumor indications, small molecule targeted drugs.
Exclusion criterion 2
Within 2 weeks prior to the first administration of the study drug, the subject had received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), albumin infusion and renal replacement therapy.
Exclusion criterion 3
Currently has active infection and requires systemic anti-infection treatment (such as acute bacterial infection, tuberculosis, active hepatitis B/ C, active syphilis, etc.). Active hepatitis B is defined as: HBsAg or HBcAb test result is positive or exceeds the normal reference range, accompanied by hepatitis B virus titer > 2500 copies/mL or 500 IU/mL (excluding subjects who received anti-hepatitis B virus treatment for at least 14 days, HBV-DNA降至≤ 2500 copies/mL or 500 IU/mL, and agreed to continue treatment during the study period); active hepatitis C is defined as: hepatitis C antibody positive or exceeds the normal reference range and HCV-RNA positive; syphilis-specific antibody positive; HIV antibody positive;
Exclusion criterion 10
Within the 5 years prior to the administration of 177Lu-HX02, the subject had any other active malignant tumors (excluding surgically resected and non-recurrent skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical cancer or other in situ cancers);
Exclusion criterion 12
ECOG score 0 to 1, able to tolerate PET/CT and SPECT/CT examinations;
Inclusion criterion 3
Bone marrow Neutrophil count ≥ 1.5×109/L and white blood cell count ≥ 2.5×109/L; Platelets ≥ 100×109/L; Hemoglobin ≥ 90 g/L;
Inclusion criterion 11
Liver function Total bilirubin ≤ 1.5×ULN (for liver metastasis subjects, total bilirubin ≤ 2×ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3×ULN (for liver metastasis subjects, ALT and AST < 5×ULN); Albumin > 30 g/L;
Inclusion criterion 12
Renal function Serum creatinine ≤ 1.5×ULN and creatinine clearance rate ≥ 50 mL/min;
Inclusion criterion 13
Coagulation function International normalized ratio (INR) ≤ 2.0, activated partial thromboplastin time (APTT) ≤ 1.5×ULN. Exception: Subjects receiving warfarin anticoagulation therapy can have INR 2 to ≤ 3;
Inclusion criterion 14
68Ga-HX01 PET/CT imaging positive. Defined as at least one lesion in the 68Ga-HX01 PET/CT imaging having SUVmax ≥ 3.0 or tumor-to-liver ratio (SUVmax/SUVmean) (T/L ratio) > 1;
Inclusion criterion 7
The medical history, computed tomography (CT) or magnetic resonance imaging (MRI) examination indicated the presence of central nervous system (CNS) metastatic lesions. Excluding: CNS metastatic lesions that have undergone radiotherapy or surgery, the subject did not use corticosteroids, anticonvulsants, or diuretics to control symptoms within 2 weeks prior to the first administration, the imaging indicated no progression or new onset of brain lesions, and there were no neurological symptoms.
Exclusion criterion 4
Pregnant women;
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07920822, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Have a thorough understanding of this study and have voluntarily signed the informed consent form;
- Age 18 to 75 years old, gender not restricted;
- ECOG score 0 to 1, able to tolerate PET/CT and SPECT/CT examinations;
- Expected survival period ≥ 6 months;
- Histologically or cytologically diagnosed as advanced malignant solid tumor;
- Previous standard treatment failed;
- 68Ga-HX01 PET/CT imaging positive. Defined as at least one lesion in the 68Ga-HX01 PET/CT imaging having SUVmax ≥ 3.0 or tumor-to-liver ratio (SUVmax/SUVmean) (T/L ratio) > 1;
- According to RECIST 1.1 standard, at least one measurable tumor lesion. For lesions that have received previous radiotherapy, the lesion can be included in the measurable lesion only when there is clear disease progression after radiotherapy;
- Toxicity of previous anti-tumor treatment (such as previous chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) has recovered to ≤ grade 1 level (except for hair loss);
- The functional level of organs must meet the following requirements:
- Bone marrow Neutrophil count ≥ 1.5×109/L and white blood cell count ≥ 2.5×109/L; Platelets ≥ 100×109/L; Hemoglobin ≥ 90 g/L;
- Liver function Total bilirubin ≤ 1.5×ULN (for liver metastasis subjects, total bilirubin ≤ 2×ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3×ULN (for liver metastasis subjects, ALT and AST < 5×ULN); Albumin > 30 g/L;
- Renal function Serum creatinine ≤ 1.5×ULN and creatinine clearance rate ≥ 50 mL/min;
- Coagulation function International normalized ratio (INR) ≤ 2.0, activated partial thromboplastin time (APTT) ≤ 1.5×ULN. Exception: Subjects receiving warfarin anticoagulation therapy can have INR 2 to ≤ 3;
- Pregnant women of childbearing age need negative pregnancy test results. Subjects with reproductive capacity (and their partners) voluntarily use effective contraceptive methods during the treatment period and within 6 months after the last use of the investigational drug, such as condoms, oral or injectable contraceptives, etc.
Exclusion Criteria:
- Within the 3 months prior to the administration of 177Lu-HX02, the subject had received radiotherapy drugs, including but not limited to: lutetium-177, radium-223, etc.
- Within the 4 weeks prior to the administration of 177Lu-HX02, the subject had undergone major surgery, chemotherapy, biological therapy, immunotherapy, endocrine therapy (except hormone replacement), large molecule targeted therapy or off-label drug treatment. Within the 2 weeks prior to administration, the subject had received local palliative radiotherapy, traditional Chinese medicine with anti-tumor indications, small molecule targeted drugs.
- Within 2 weeks prior to the first administration of the study drug, the subject had received blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), albumin infusion and renal replacement therapy.
- The medical history, computed tomography (CT) or magnetic resonance imaging (MRI) examination indicated the presence of central nervous system (CNS) metastatic lesions. Excluding: CNS metastatic lesions that have undergone radiotherapy or surgery, the subject did not use corticosteroids, anticonvulsants, or diuretics to control symptoms within 2 weeks prior to the first administration, the imaging indicated no progression or new onset of brain lesions, and there were no neurological symptoms.
- Suffering from severe cardiovascular diseases, including but not limited to the following conditions:
- Within 6 months prior to administration, suffered from acute myocardial infarction, unstable angina pectoris, or received coronary angioplasty or stent;
- New York Heart Association class II to IV congestive heart failure or left ventricular ejection fraction (LVEF) < 50% or within the lower limit of the normal range;
- Uncontrolled hypertension (even with optimal treatment, with systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
- Baseline electrocardiogram QTcF interval prolonged (> 480 ms);
- Currently has active infection and requires systemic anti-infection treatment (such as acute bacterial infection, tuberculosis, active hepatitis B/ C, active syphilis, etc.). Active hepatitis B is defined as: HBsAg or HBcAb test result is positive or exceeds the normal reference range, accompanied by hepatitis B virus titer > 2500 copies/mL or 500 IU/mL (excluding subjects who received anti-hepatitis B virus treatment for at least 14 days, HBV-DNA降至≤ 2500 copies/mL or 500 IU/mL, and agreed to continue treatment during the study period); active hepatitis C is defined as: hepatitis C antibody positive or exceeds the normal reference range and HCV-RNA positive; syphilis-specific antibody positive; HIV antibody positive;
- Non-infectious pneumonia requiring hormone treatment and radiation pneumonitis, hemodynamic-altering thrombotic events, active bleeding events or other serious complications;
- Within the 5 years prior to the administration of 177Lu-HX02, the subject had any other active malignant tumors (excluding surgically resected and non-recurrent skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical cancer or other in situ cancers);
- Known to be allergic to the components of the study drug or its analogues;
- Any person with difficulty in urination or urinary incontinence;
- Suffering from claustrophobia or other conditions that prevent cooperation in PET/CT or SPECT/CT examinations;
- Patients with mental disorders such as depression, schizophrenia, delusion, hallucination or suicidal ideation;
- Pregnant women;
- Other situations that the investigator considers the subject is not suitable to participate in this study.
Quoted from ClinicalTrials.gov, NCT07920822, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07920822, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.